{"id":"W2098775844","doi":"10.1056/nejmoa0910383","title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2775,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"U.S. Army Medical Research and Development Command; National Cancer Institute; Genentech; Sanofi; Eli Lilly and Company; California Breast Cancer Research Program; GlaxoSmithKline; Amgen","keywords":"Trastuzumab; Medicine; Anthracycline; Internal medicine; Regimen; Docetaxel; Carboplatin; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Cancer; Chemotherapy; Surgery; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}